MIGAL Galilee Research Institute
We study the molecular basis of chronic diseases, focusing on the function of microRNAs. MicroRNAs may act as a functional link between different chronic diseases, and hold promise as potential biomarkers and therapeutic targets. Specifically, we are interested in:
MicroRNAs as a mechanistic link between metabolic disease and cancer
Discovery of microRNA-based biomarkers in body fluids
Gene expression analysis
microRNA target validation
Quantification and manipulation of microRNA levels in cells, tissues and biofluids
Interested in collaborating on
Although I'm open to many types of collaboration, as a molecular biologist, I'm specifically looking for clinicians who would have access to samples, resources and knowledge complementary to my own.
Selected publications on lncRNA
Elevated Levels of miR-122 in Serum May Contribute to Improved Endothelial Function and Lower Oncologic Risk Following Bariatric Surgery. Blum A, Yehuda H, Geron N, Meerson A. Isr Med Assoc J. 2017, 19(10):620-624.
Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF-α. Meerson A, Traurig M, Ossowski V, Fleming JM, Mullins M, Baier LJ. Diabetologia. 2013, 56(9):1971-9.
MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. Shaked I, Meerson A, Wolf Y, Avni R, Greenberg D, Gilboa-Geffen A, Soreq H. Immunity. 2009, 31(6):965-73.
MicroRNA modulation of megakaryoblast fate involves cholinergic signaling. Guimaraes-Sternberg C, Meerson A, Shaked I, Soreq H. Leuk Res. 2006, 30(5):583-95.